Akero Therapeutics

$27.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.66 (-2.38%) Today
-$0.09 (-0.33%) As of 8:00 PM UTC after-hours

Why Robinhood?

You can buy or sell AKRO and other stocks, options, and ETFs commission-free!

About AKRO

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

CEO
Andrew Cheng
Employees
21
Headquarters
South San Francisco, California
Founded
2017
Market Cap
943.94M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
294.81K
High Today
$27.75
Low Today
$26.80
Open Price
$27.67
Volume
241.59K
52 Week High
$41.16
52 Week Low
$18.36

AKRO Earnings

-$0.86
-$0.57
-$0.29
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 13, Pre-Market

You May Also Like

ACAHU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure